Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 0.65 |
| ▸ | CDK2 | P24941 | 5/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | PI4KA | P42356 | 1/20 | 0.54 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.54 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | PRKACB | P22694 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19618133 | 0.88 | CDK1 (0.50) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL19760046 | 0.88 | CDK1 (0.50) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL9884992 | 0.86 | ADORA2A (0.58) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL4572147 | 0.86 | ADORA2A (0.58) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL179414 | 0.86 | CDK1 (0.48) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL253874 | 0.86 | ADORA2A (0.58) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL179348 | 0.86 | CDK1 (0.48) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL179415 | 0.86 | CDK1 (0.48) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL19261331 | 0.84 | CDK1 (0.46) | CDK1CDK2CCNB1CCNE1ADORA2A | |
| SCHEMBL12379217 | 0.80 | CDK1 (0.58) | CDK1CDK2CCNB1CCNE1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| EP-3613743-B1 | PROCESSES FOR THE PREPARATION OF 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE DERIVATIVES | INTELLIKINE LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2019-09-26 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-9822131-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2017-10-05 | — | — | US | disclosed |
| US-9738644-B2 | Chemical compounds, compositions and methods for kinase modulation | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9655892-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2017-05-23 | — | — | US | disclosed |
| US-9527847-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8828998-B2 | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC (US) | 2014-07-24 | — | — | US | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8703777-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8569323-B2 | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE, LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088099-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | CDK1 69/4885CDK2 97/4885CCNB1 632/4885 |
| US-20140206684-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CDK1 67/4885CDK2 75/4885CCNB1 612/4885 |
| US-20190290636-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CDK1 221/4885CDK2 128/4885CCNB1 1882/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | CDK1 2791/4885CDK2 3708/4885CCNB1 193/4885 |
| US-20200222384-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | CDK1 110/4885CDK2 77/4885CCNB1 659/4885 |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CDK1 88/4885CDK2 85/4885CCNB1 683/4885 |
| US-20140120083-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | CDK1 88/4885CDK2 85/4885CCNB1 683/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | CDK1 64/4885CDK2 38/4885CCNB1 644/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | CDK1 110/4885CDK2 77/4885CCNB1 659/4885 |
| US-20170281614-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CDK1 221/4885CDK2 128/4885CCNB1 1882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.